VYNE Therapeutics Inc. (VYNE)

2.7298 +0.0798 (+3.01%) 市場開市。 截至 12:00PM EDT。

VYNE Therapeutics Inc.

685 Route 202/206 N
Suite 301
Bridgewater, NJ 08807
United States
800 775 7936
https://www.vynetherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 10

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. David T. Domzalski	CEO, President & Director	1.61M	無	1967
Dr. Iain A. Stuart Ph.D.	Chief Scientific Officer	856.82k	無	1973
Ms. Mutya Harsch J.D.	General Counsel, Chief Legal Officer & Company Secretary	817.97k	無	1975
Mr. Tyler Zeronda	CFO & Treasurer	無	無	1987
Dr. Darrell S. Rigel FAAD, M.D.	Consultant	40.2k	無	1951

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

公司管治

截至 無 止，VYNE Therapeutics Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。